Cargando…

The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study

The potential of viruses as appropriate vectors for the development of new therapeutic strategies, as well as for the design of molecular (DNA, RNA, and/or protein) vaccines via substitution of nucleotide sequences, has been proven. Among the most appropriate DNA and/or RNA fragments, members belong...

Descripción completa

Detalles Bibliográficos
Autores principales: Sainova, Iskra, Kolyovska, Vera, Ilieva, Iliana, Markova, Tzvetanka, Dimitrova-Dikanarova, Dimitrina, Hadjiolova, Radka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386085/
https://www.ncbi.nlm.nih.gov/pubmed/37515042
http://dx.doi.org/10.3390/vaccines11071226
_version_ 1785081573441273856
author Sainova, Iskra
Kolyovska, Vera
Ilieva, Iliana
Markova, Tzvetanka
Dimitrova-Dikanarova, Dimitrina
Hadjiolova, Radka
author_facet Sainova, Iskra
Kolyovska, Vera
Ilieva, Iliana
Markova, Tzvetanka
Dimitrova-Dikanarova, Dimitrina
Hadjiolova, Radka
author_sort Sainova, Iskra
collection PubMed
description The potential of viruses as appropriate vectors for the development of new therapeutic strategies, as well as for the design of molecular (DNA, RNA, and/or protein) vaccines via substitution of nucleotide sequences, has been proven. Among the most appropriate DNA and/or RNA fragments, members belonging to families Parvoviridae (particularly adeno-associated virus, AAV) and Poxviridae have frequently been suggested for this purpose. In previous studies, the vaccine avipoxvirus strains FK (fowl) and Dessau (pigeon) have been proven able to infect mammalian cells (as well as avian cells), and to replicate productively in a small number of them; thus, we may be able to adapt them using incubation, and in these conditions. Additionally, we have previously proved, based on AAV recombinant DNA vectors, that it is possible to transfer appropriate genes of interest via mouse embryonic stem cells (mESCs). In the current study, we develop methods for the application of the same vaccine avipoxviral strains, based on the AAV DNA genome recombinant constructs, to be used for gene transfer in cells, for the transfer of DNA and/or RNA fragments (for the suppression of unwanted viral and/or cellular genes), and for the production of molecular (DNA, RNA, and/or protein) anti-cancer and anti-viral vaccines. To this end, sub-populations of embryonic mammalian cells infected with the two forms of both vaccine avipoxviral strains were frozen in the presence of cryo-protector dimethylsulfoxide (DMSO), subsequently thawed, and re-incubated. In most cases, the titers of the intra-cellular forms of the two strains were higher than those of their extra-cellular forms. These data were explained by the probable existence of the intra-cellular forms as different sub-forms, including those integrated in the cellular genome proviruses at a given stage of the cellular infection, and suggest the possibility of transferring nucleotide (DNA and/or RNA) fragments between cellular and viral genomes; this is due to the influence of activated fusion processes on DMSO, as well as drastic temperature variations.
format Online
Article
Text
id pubmed-10386085
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103860852023-07-30 The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study Sainova, Iskra Kolyovska, Vera Ilieva, Iliana Markova, Tzvetanka Dimitrova-Dikanarova, Dimitrina Hadjiolova, Radka Vaccines (Basel) Article The potential of viruses as appropriate vectors for the development of new therapeutic strategies, as well as for the design of molecular (DNA, RNA, and/or protein) vaccines via substitution of nucleotide sequences, has been proven. Among the most appropriate DNA and/or RNA fragments, members belonging to families Parvoviridae (particularly adeno-associated virus, AAV) and Poxviridae have frequently been suggested for this purpose. In previous studies, the vaccine avipoxvirus strains FK (fowl) and Dessau (pigeon) have been proven able to infect mammalian cells (as well as avian cells), and to replicate productively in a small number of them; thus, we may be able to adapt them using incubation, and in these conditions. Additionally, we have previously proved, based on AAV recombinant DNA vectors, that it is possible to transfer appropriate genes of interest via mouse embryonic stem cells (mESCs). In the current study, we develop methods for the application of the same vaccine avipoxviral strains, based on the AAV DNA genome recombinant constructs, to be used for gene transfer in cells, for the transfer of DNA and/or RNA fragments (for the suppression of unwanted viral and/or cellular genes), and for the production of molecular (DNA, RNA, and/or protein) anti-cancer and anti-viral vaccines. To this end, sub-populations of embryonic mammalian cells infected with the two forms of both vaccine avipoxviral strains were frozen in the presence of cryo-protector dimethylsulfoxide (DMSO), subsequently thawed, and re-incubated. In most cases, the titers of the intra-cellular forms of the two strains were higher than those of their extra-cellular forms. These data were explained by the probable existence of the intra-cellular forms as different sub-forms, including those integrated in the cellular genome proviruses at a given stage of the cellular infection, and suggest the possibility of transferring nucleotide (DNA and/or RNA) fragments between cellular and viral genomes; this is due to the influence of activated fusion processes on DMSO, as well as drastic temperature variations. MDPI 2023-07-11 /pmc/articles/PMC10386085/ /pubmed/37515042 http://dx.doi.org/10.3390/vaccines11071226 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sainova, Iskra
Kolyovska, Vera
Ilieva, Iliana
Markova, Tzvetanka
Dimitrova-Dikanarova, Dimitrina
Hadjiolova, Radka
The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study
title The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study
title_full The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study
title_fullStr The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study
title_full_unstemmed The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study
title_short The Development of Methods for the Production of New Molecular Vaccines and Appropriate RNA Fragments to Counteract Unwanted Genes: A Pilot Study
title_sort development of methods for the production of new molecular vaccines and appropriate rna fragments to counteract unwanted genes: a pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386085/
https://www.ncbi.nlm.nih.gov/pubmed/37515042
http://dx.doi.org/10.3390/vaccines11071226
work_keys_str_mv AT sainovaiskra thedevelopmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT kolyovskavera thedevelopmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT ilievailiana thedevelopmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT markovatzvetanka thedevelopmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT dimitrovadikanarovadimitrina thedevelopmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT hadjiolovaradka thedevelopmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT sainovaiskra developmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT kolyovskavera developmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT ilievailiana developmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT markovatzvetanka developmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT dimitrovadikanarovadimitrina developmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy
AT hadjiolovaradka developmentofmethodsfortheproductionofnewmolecularvaccinesandappropriaternafragmentstocounteractunwantedgenesapilotstudy